An observational study in Inflammatory Rhinitis, sponsored by Nantes University Hospital. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-08.
Sponsored by Nantes University Hospital · Observational
Inflammatory rhinitis is a side effect observed in patients treated with biotherapies in the context of chronic bowel disease (IBD) or spondylartrhopathy (SPA). This damage is still poorly described in the literature. I The objective of this study is to study the associated characteristics of crustal rhinitis in a cohort of patients treated with biotherapy for chronic inflammatory disease (IBD, SPA, psoriasis).
Inflammatory rhinitis is a side effect observed in patients treated with biotherapies in the context of chronic bowel disease (IBD) or spondylartrhopathy (SPA). This damage is still poorly described in the literature. It can occur in isolation or in association with a fold pustulose table, which differs from the classic fold pustulose described by Cribier et al in autoimmune diseases by the presence of staphylococcus aureus in the pustules. Some authors also describe associated paradoxical psoriasiform reactions or an impetigo. In our experience, this condition is more frequently found in patients treated for IBD or SPA and has a clinically characteristic fissure appearance. Thus, the semiology but also the epidemiology of this crusty rhinitis is still poorly described.
The objective of this study is to study the associated characteristics of crustal rhinitis in a cohort of patients treated with biotherapy for chronic inflammatory disease (IBD, SPA, psoriasis).
Patient recruitment will take place over a one-year period, in a multi-centre manner (Angers and Nantes University Hospital) with prospective data collection in the form of a questionnaire and clinical evaluation during a dermatology consultation planned in the traditional care pathway for the follow-up of patients with skin manifestations during biotherapy treatment.
1,105 studies on the registry are indexed under Rhinitis; 65 are open to participants now.
This study's enrollment of 356 is above the median of 141 across 172 observational studies indexed under Rhinitis.
Browse Rhinitis studies →Nantes University Hospital is the lead sponsor of 825 studies on the registry; 195 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Recruitment of patients on biotherapies that meet the inclusion criteria as exhaustively as possible.
Translated with www.DeepL.com/Translator
Exclusion Criteria:
(presence of certain antecedents, weight, height, current or past existence of inflammatory rhinitis) and a second by the specialist doctor (pathology at the origin of the start of biotherapy, year of beginning of treatment, previous biotherapies over the last 3 years).
Prevalence of inflammatory rhinitis
Presence of inflammatory rhinitis yes/no
Time frame: through study completion, an average of 1 year
Characteristics associated with Patient-related characteristics in inflammatory rhinitis.
* Age * Tobacco use yes/no * Diabetes yes/no * Verneuil disease yes/no * Psoriasis yes/no * Eczema in childhood yes/no * Underlying pathology (type, start year) * Previous biotherapies and duration of exposure over the last 3 years yes/no
Time frame: through study completion, an average of 1 year
Characteristics of rhinitis.
* Delays between the start of treatment and the onset of symptoms * Treatment under which rhinitis occurred * Rhinitis stage * Permanent or recurring, unilateral or bilateral * Associated functional signs (rhinorrhea, pain...) * Quality of Life (DLQI) * Presence of documented endonasal staphylococcus yes/no * Positivity of anti-nuclear antibodies yes/no * Type of treatment carried out
Time frame: through study completion, an average of 1 year
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nantes University Hospital